[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566013":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":46,"collaborators":19,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":19,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":19,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":19,"overallStatus":67,"whyStopped":19,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},{"fullName":5,"class":6},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TQB2252 injection","EXPERIMENTAL","This product is administered via intravenous infusion, with recommended doses of 600mg TQB2223 monoclonal antibody and 200mg penpulimab injection, administered once every 3 weeks.",[13],"Drug: TQB2252 injection",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","TQB2252 injection is a compound preparation of TQB2223 monoclonal antibody (LAG-3) and penpulimab (PD-1), with a specification of 300mg TQB2223 monoclonal antibody and 100mg (20ml) penpulimab per bottle.",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Xing Zhang, Doctor","CONTACT","13610223691","zhangxing@sysucc.org.cn",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},"Qingqing Cai, Doctor","13798101121","caiqq@sysucc.org.cn",[31],{"facility":32,"status":19,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Guangdong provincial people's hospital","Guangzhou","Guangdong","519041","China","CN",{"type":39,"coordinates":40},"Point",[41,42],113.25,23.11667,{"lat":42,"lon":41},[45],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"type":47,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100566013","phase-1-a-multicenter-open-label-phase-i-clinical-trial-evaluating-the-safety-and-pharmacokinetics-of-tqb2252-injection-in-subjects-with-advanced-malignant-tumors-100566013",false,"NCT06649656","A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors","Inclusion Criteria:\n\n* The subjects voluntarily joined this study, signed an informed consent form, and showed good compliance;\n* 18 years old ≤ 75 years old (calculated from the date of signing the informed consent form);\n* Electrocorticogram (ECOG) score ranges from 0 to 1 points;\n* Expected survival is greater than 12 weeks；\n* Confirmed to have at least one measurable lesion according to RECIST 1.1 (solid tumor) or Lugano 2014 (lymphoma) criteria；\n* Late stage malignant tumor subjects who have failed standard treatment or lack effective treatment；\n* Women of childbearing age should agree to use effective contraceptive measures during the study period and for 6 months after the end of the study; Men should agree to use effective contraceptive measures during the study period and for 6 months after the end of the study period.\n\nExclusion Criteria:\n\n* Has experienced or currently has other malignant tumors within the past 5 years prior to the first use of medication;\n* There are multiple factors that affect diseases related to intravenous injection and venous blood collection;\n* The adverse reactions of previous anti-tumor treatments have not recovered to a Common Terminology Criteria for Adverse Events (CTCAE) v5.0 score of ≤ 1;\n* Individuals who have undergone major surgical treatment, significant traumatic injury, or are expected to undergo major surgery during the expected study treatment period within 4 weeks prior to the first use of medication;\n* Subjects who experience any bleeding or bleeding events ≥ CTCAE grade 3 within 4 weeks prior to the first administration;\n* An arterial\u002Fvenous thrombotic event occurred within 6 months prior to the first administration;\n* Active viral hepatitis with poor control;\n* Active syphilis infected individuals in need of treatment;\n* History of active pulmonary tuberculosis, idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, radiation pneumonitis requiring treatment, or clinically symptomatic active pneumonia;\n* Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders;\n* Diagnosed with immunodeficiency or undergoing systemic glucocorticoid therapy or any other form of immunosuppressive therapy due to a history of hepatic encephalopathy;\n* Previously experienced grade 3 or higher adverse reactions related to immunotherapy;\n* Suffering from significant cardiovascular disease;\n* Active or uncontrolled severe infections;\n* Patients with renal failure requiring hemodialysis or peritoneal dialysis;\n* History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases;\n* Individuals with epilepsy who require treatment;\n* Previously received treatment with similar anti-lag3 drugs.",true,"ALL","18 Years","75 Years",{"count":59,"type":60},100,"ESTIMATED","INTERVENTIONAL",[63],"PHASE1","This study is a multicenter, single arm, and open design Phase I clinical trial aimed at evaluating the safety, Pharmacokinetics (PK) characteristics, immunogenicity, and preliminary efficacy of TQB2252 injection in subjects with advanced malignant tumors.",[66],"Advanced Cancers","NOT_YET_RECRUITING","2024-10-17",{"date":70,"type":71},"2024-10-21","ACTUAL",{"date":73,"type":60},"2024-11",{"date":75,"type":60},"2026-12",{"name":77,"class":6},"Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.",1]